Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.89 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.89 |
| ▸ | SSTR5 | P35346 | 7/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 6/20 | 0.43 |
| ▸ | SSTR2 | P30874 | 5/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | TERF2 | Q15554 | 1/20 | 0.40 |
| ▸ | TERF2IP | Q9NYB0 | 2/20 | 0.40 |
| ▸ | LDHB | P07195 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21335212 | 1.00 | KDM1A (0.89) | KDM1ARCOR1SSTR5SSTR4SSTR2 | |
| SCHEMBL21335213 | 0.99 | KDM1A (0.87) | KDM1ARCOR1SSTR5SSTR4SSTR2 | |
| SCHEMBL22105878 | 0.99 | KDM1A (0.87) | KDM1ARCOR1SSTR5SSTR4SSTR2 | |
| SCHEMBL21335214 | 0.98 | KDM1A (0.91) | KDM1ARCOR1SSTR5SSTR4SSTR2 | |
| SCHEMBL16426298 | 0.98 | KDM1A (0.91) | KDM1ARCOR1SSTR5SSTR4SSTR2 | |
| SCHEMBL16426297 | 0.98 | KDM1A (0.88) | KDM1ARCOR1SSTR5SSTR4SSTR2 | |
| SCHEMBL21335145 | 0.98 | KDM1A (0.88) | KDM1ARCOR1SSTR5SSTR4SSTR2 | |
| SCHEMBL21335093 | 0.97 | KDM1A (0.90) | KDM1ARCOR1SSTR5SSTR4SSTR2 | |
| SCHEMBL21335230 | 0.97 | KDM1A (0.90) | KDM1ARCOR1SSTR5SSTR4SSTR2 | |
| SCHEMBL21335094 | 0.97 | KDM1A (0.90) | KDM1ARCOR1SSTR5SSTR4SSTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160222061-A1 | Polymyxin Derivatives and Their Use in Combination Therapy Together with Different Antibiotics | NEW PHARMA LICENCE HOLDINGS LIMITED (MT) | 2016-08-04 | — | — | US | disclosed |
| US-9234006-B2 | Compounds | NOVACTA BIOSYSTEMS LIMITED (GB) | 2016-01-12 | — | — | US | disclosed |
| US-20150031602-A1 | Compounds | CANTAB ANTI-INFECTIVES LIMITED (UK) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222061-A1 | Polymyxin Derivatives and Their Use in Combination Therapy Together with Different Antibiotics | MRPS18A, MRPL21, RRP1B | KDM1A 3699/4885RCOR1 1566/4885SSTR5 988/4885 |
| US-20150031602-A1 | Compounds | NRDC, TLR6, TLR7 | KDM1A 4068/4885RCOR1 1286/4885SSTR5 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.